WS12.1 An exploratory study to determine the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F/F).

Saved in:
Bibliographic Details
Title: WS12.1 An exploratory study to determine the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F/F).
Authors: Stahl, M. (AUTHOR), Roehmel, J. (AUTHOR), Eichinger, M. (AUTHOR), Doellinger, F. (AUTHOR), Naehrlich, L. (AUTHOR), Kopp, M.V. (AUTHOR), Dittrich, A.-M. (AUTHOR), Lee, C. (AUTHOR), Sommerburg, O. (AUTHOR), Tian, S. (AUTHOR), Xu, T. (AUTHOR), Wu, P. (AUTHOR), Joshi, A. (AUTHOR), Duncan, M. (AUTHOR), Wielpütz, M.O. (AUTHOR), Mall, M. (AUTHOR)
Source: Journal of Cystic Fibrosis. 2021 Supplement, Vol. 20, pS22-S23. 2p.
Database: Academic Search Ultimate
Description
ISSN:15691993
DOI:10.1016/S1569-1993(21)00981-4